Skip to main content

Table 4 Characteristics of patients treated with ICS/LABA fixed combinations for at least 4 weeks before the 12-month follow-up visit

From: 1-year prospective real life monitoring of asthma control and quality of life in Italy

  Total n = 569 BDP/F extrafine n = 301 BUD/F n = 145 FP/S n = 123 Overall p-value
Level of asthma control, n (%)      0.001(1)
  Fully controlled 108 (19.0) 77 (25.6) 12 (8.3) 19 (15.4)  
  Controlled 351 (61.7) 173 (57.5) 102 (70.3) 76 (61.8)  
  Partly controlled 68 (12.0) 31 (10.3) 18 (12.4) 19 (15.4)  
  Uncontrolled 42 (7.4) 20 (6.6) 13 (9.0) 9 (7.3)  
Current smokers, n (%) 110 (19.3) 69 (22.9) 25 (17.2) 16 (13.0) 0.617
  Fully controlled 25 (22.7) 20 (29.0) 3 (12.0) 2 (12.5) 0.135
  Controlled 66 (60.0) 39 (56.5) 17 (68.0) 10 (62.5)  
  Partly controlled 12 (10.9) 7 (10.1) 3 (12.0) 2 (12.5)  
  Uncontrolled 7 (6.4) 3 (4.4) 2 (8.0) 2 (12.5)  
ACT score, mean (SD) 21.5 (3.4) 22.0 (3.4) 20.7 (3.6) 21.3 (3.3) <0.001(2)
Improvement of 3 points in ACT score, n (%) 493 (86.6) 268 (89.0) 116 (80.0) 109 (88.6) 0.024(3)
Daily Dose of ICS, n 537 287 141 122  
  Mean mcg (SD) NA 318.8 (114.3) 651.1 (291.2) 750.6 (371.7) <0.001(4)
Patients with exacerbation, n (%) (5) 84 (14.8) 40 (13.3) 19 (13.1) 25 (20.3) 0.145
  1. BDP/F: beclomethasone/formoterol; BUD/F: budesonide/formoterol; FP/S: fluticasone/salmeterol; (1) Bonferroni’s corrected p = 0.001 BDP/F vs. BUD/F; (2) Bonferroni’s corrected p < 0.001 BDP/F vs. BUD/F; Bonferroni’s corrected p = 0.039 BDP/F vs. FP/S; (3) Bonferroni’s corrected p = 0.029 BDP/F vs. BUD/F; (4) Bonferroni’s corrected p < 0.001 BDP/F vs. BUD/F and FP/S; Bonferroni’s corrected p < 0.001 BUD/F vs. FP/S; (5) Reported in the last 3 months before the 12-month visit.